Loading…

Trypanozoma cruzi Infection in Patients Undergoing Solid Organ Transplantation

Abstract Background It is estimated that 1.5 million people are infected with T. cruzi in Argentina (4%). Chagas reactivation rate (R) in patients with solid organ transplantation (SOT) is around 33%, being higher in cardiac transplantation (Tx). Objective To describe the clinical characteristics, e...

Full description

Saved in:
Bibliographic Details
Published in:Open forum infectious diseases 2017-10, Vol.4 (suppl_1), p.S702-S702
Main Authors: Mañez, Noelia, Alderete, Manuel, Benso, Jose, Valledor, Alejandra, Smud, Astrid, Schijman, Alejandro, Besuschio, Susana, Barcan, Laura
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page S702
container_issue suppl_1
container_start_page S702
container_title Open forum infectious diseases
container_volume 4
creator Mañez, Noelia
Alderete, Manuel
Benso, Jose
Valledor, Alejandra
Smud, Astrid
Schijman, Alejandro
Besuschio, Susana
Barcan, Laura
description Abstract Background It is estimated that 1.5 million people are infected with T. cruzi in Argentina (4%). Chagas reactivation rate (R) in patients with solid organ transplantation (SOT) is around 33%, being higher in cardiac transplantation (Tx). Objective To describe the clinical characteristics, evolution, mortality, to evaluate reactivation risk factors and to analyze the usefulness of molecular tests in patients undergoing at SOT with Chagas’ disease risk (ChR) (R or Donor-derived transmission, -DT-), in a hospital in our country. Methods Retrospective cohort from all the patients who received an SOT in our hospital from January 1988 to March 2017. All patients with ChR: either R or DT were analyzed. Inclusion: survival more 30 days and 6 months of follow-up or until death. We performed post-Tx monitoring with parasitaemia (Strout), and serial whole blood polymerase chain reaction (PCR) testing, weekly until 2 months, every 2 weeks until the sixth month and monthly until the year, later annual. PCR monitoring is done since 2006. Results We performed 1932 SOT in 29 years: 54 SOT in patients with ChR, 46 chagasic recipients (CR) and 8 chagasic donors (CD) to negative recipient 24/46 (52%) presented R, (see Table 1), 4 had more than one episode. Time to first R was 67 days (r = 3–296, median 30 days). At the time of the R Strout was performed in 19 episode 13 were negative, PCR was positive in 10/10 of perfcormed test, 32% vs. 100% (P = 0.001). Clinical R: 5 episode in 4 patients (panniculitis 3, 1 with myocarditis, 1 myocarditis). Strout was negative in 2 of these, in the other episode monitoring had not been performed. Immunosuppression (IS): there were no differences in the IS, (induction and treatment of rejections). Reactivation: 21/24 responded to treatment, 2 spontaneously PCR-negative, 1 died. Mortality: 6/24 (25%) in pt. R and 2/17 (12%) in pt no R (P = ns), not related mortality. DT occurred in 1/ 3 liver and in 0/5 renal recipients. Type of Tx All Reactivation Clinic Liver (L) 786 7/26 (27%) 1/7 (14%) Heart 241 13/23 (56%) 2/13 (15%) Kidney (K) 613 2/5 (40%) 1/2 (50%) Lung 105 1/2 (50%) 0 LK 26 1/1 (100% 0 Others 161 0 0 Conclusion PCR was more sensitive than Strout for detection of R or transmission. There was no clinical R in pt monitored by PCR. Also PCR sensitivity allow safe acceptance of Chagasic organs. Disclosures All authors: No reported disclosures.
doi_str_mv 10.1093/ofid/ofx163.1883
format article
fullrecord <record><control><sourceid>oup_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5631452</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ofid/ofx163.1883</oup_id><sourcerecordid>10.1093/ofid/ofx163.1883</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1743-4c37172115ea1849c244282494f5e5befd95e039c01d888ab024e6a58e76044c3</originalsourceid><addsrcrecordid>eNqFkE1LAzEQhoMoWGrvHnOXrfncTS6CFD8KxQq255Bms2tkmyzJVrS_3l1WRE9eZgZmnpfhAeASozlGkl6HypV9-cA5nWMh6AmYEEpEJiQvTn_N52CW0htCCGPEUSEn4GkTP1vtwzHsNTTxcHRw6StrOhc8dB4-685Z3yW49aWNdXC-hi-hcSVcx1p7uInap7bRvtMDcgHOKt0kO_vuU7C9v9ssHrPV-mG5uF1lBheMZszQAhcEY241FkwawhgRhElWcct3tiolt4hKg3AphNA7RJjNNRe2yBHr6Sm4GXPbw25vS9O_GHWj2uj2On6qoJ36u_HuVdXhXfGcYsZJH4DGABNDStFWPyxGanCqBqdqdKoGpz1yNSLh0P5__QUCUXvT</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Trypanozoma cruzi Infection in Patients Undergoing Solid Organ Transplantation</title><source>OUP_牛津大学出版社OA刊</source><source>PubMed Central</source><creator>Mañez, Noelia ; Alderete, Manuel ; Benso, Jose ; Valledor, Alejandra ; Smud, Astrid ; Schijman, Alejandro ; Besuschio, Susana ; Barcan, Laura</creator><creatorcontrib>Mañez, Noelia ; Alderete, Manuel ; Benso, Jose ; Valledor, Alejandra ; Smud, Astrid ; Schijman, Alejandro ; Besuschio, Susana ; Barcan, Laura</creatorcontrib><description>Abstract Background It is estimated that 1.5 million people are infected with T. cruzi in Argentina (4%). Chagas reactivation rate (R) in patients with solid organ transplantation (SOT) is around 33%, being higher in cardiac transplantation (Tx). Objective To describe the clinical characteristics, evolution, mortality, to evaluate reactivation risk factors and to analyze the usefulness of molecular tests in patients undergoing at SOT with Chagas’ disease risk (ChR) (R or Donor-derived transmission, -DT-), in a hospital in our country. Methods Retrospective cohort from all the patients who received an SOT in our hospital from January 1988 to March 2017. All patients with ChR: either R or DT were analyzed. Inclusion: survival more 30 days and 6 months of follow-up or until death. We performed post-Tx monitoring with parasitaemia (Strout), and serial whole blood polymerase chain reaction (PCR) testing, weekly until 2 months, every 2 weeks until the sixth month and monthly until the year, later annual. PCR monitoring is done since 2006. Results We performed 1932 SOT in 29 years: 54 SOT in patients with ChR, 46 chagasic recipients (CR) and 8 chagasic donors (CD) to negative recipient 24/46 (52%) presented R, (see Table 1), 4 had more than one episode. Time to first R was 67 days (r = 3–296, median 30 days). At the time of the R Strout was performed in 19 episode 13 were negative, PCR was positive in 10/10 of perfcormed test, 32% vs. 100% (P = 0.001). Clinical R: 5 episode in 4 patients (panniculitis 3, 1 with myocarditis, 1 myocarditis). Strout was negative in 2 of these, in the other episode monitoring had not been performed. Immunosuppression (IS): there were no differences in the IS, (induction and treatment of rejections). Reactivation: 21/24 responded to treatment, 2 spontaneously PCR-negative, 1 died. Mortality: 6/24 (25%) in pt. R and 2/17 (12%) in pt no R (P = ns), not related mortality. DT occurred in 1/ 3 liver and in 0/5 renal recipients. Type of Tx All Reactivation Clinic Liver (L) 786 7/26 (27%) 1/7 (14%) Heart 241 13/23 (56%) 2/13 (15%) Kidney (K) 613 2/5 (40%) 1/2 (50%) Lung 105 1/2 (50%) 0 LK 26 1/1 (100% 0 Others 161 0 0 Conclusion PCR was more sensitive than Strout for detection of R or transmission. There was no clinical R in pt monitored by PCR. Also PCR sensitivity allow safe acceptance of Chagasic organs. Disclosures All authors: No reported disclosures.</description><identifier>ISSN: 2328-8957</identifier><identifier>EISSN: 2328-8957</identifier><identifier>DOI: 10.1093/ofid/ofx163.1883</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Abstracts</subject><ispartof>Open forum infectious diseases, 2017-10, Vol.4 (suppl_1), p.S702-S702</ispartof><rights>The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631452/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631452/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,1604,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Mañez, Noelia</creatorcontrib><creatorcontrib>Alderete, Manuel</creatorcontrib><creatorcontrib>Benso, Jose</creatorcontrib><creatorcontrib>Valledor, Alejandra</creatorcontrib><creatorcontrib>Smud, Astrid</creatorcontrib><creatorcontrib>Schijman, Alejandro</creatorcontrib><creatorcontrib>Besuschio, Susana</creatorcontrib><creatorcontrib>Barcan, Laura</creatorcontrib><title>Trypanozoma cruzi Infection in Patients Undergoing Solid Organ Transplantation</title><title>Open forum infectious diseases</title><description>Abstract Background It is estimated that 1.5 million people are infected with T. cruzi in Argentina (4%). Chagas reactivation rate (R) in patients with solid organ transplantation (SOT) is around 33%, being higher in cardiac transplantation (Tx). Objective To describe the clinical characteristics, evolution, mortality, to evaluate reactivation risk factors and to analyze the usefulness of molecular tests in patients undergoing at SOT with Chagas’ disease risk (ChR) (R or Donor-derived transmission, -DT-), in a hospital in our country. Methods Retrospective cohort from all the patients who received an SOT in our hospital from January 1988 to March 2017. All patients with ChR: either R or DT were analyzed. Inclusion: survival more 30 days and 6 months of follow-up or until death. We performed post-Tx monitoring with parasitaemia (Strout), and serial whole blood polymerase chain reaction (PCR) testing, weekly until 2 months, every 2 weeks until the sixth month and monthly until the year, later annual. PCR monitoring is done since 2006. Results We performed 1932 SOT in 29 years: 54 SOT in patients with ChR, 46 chagasic recipients (CR) and 8 chagasic donors (CD) to negative recipient 24/46 (52%) presented R, (see Table 1), 4 had more than one episode. Time to first R was 67 days (r = 3–296, median 30 days). At the time of the R Strout was performed in 19 episode 13 were negative, PCR was positive in 10/10 of perfcormed test, 32% vs. 100% (P = 0.001). Clinical R: 5 episode in 4 patients (panniculitis 3, 1 with myocarditis, 1 myocarditis). Strout was negative in 2 of these, in the other episode monitoring had not been performed. Immunosuppression (IS): there were no differences in the IS, (induction and treatment of rejections). Reactivation: 21/24 responded to treatment, 2 spontaneously PCR-negative, 1 died. Mortality: 6/24 (25%) in pt. R and 2/17 (12%) in pt no R (P = ns), not related mortality. DT occurred in 1/ 3 liver and in 0/5 renal recipients. Type of Tx All Reactivation Clinic Liver (L) 786 7/26 (27%) 1/7 (14%) Heart 241 13/23 (56%) 2/13 (15%) Kidney (K) 613 2/5 (40%) 1/2 (50%) Lung 105 1/2 (50%) 0 LK 26 1/1 (100% 0 Others 161 0 0 Conclusion PCR was more sensitive than Strout for detection of R or transmission. There was no clinical R in pt monitored by PCR. Also PCR sensitivity allow safe acceptance of Chagasic organs. Disclosures All authors: No reported disclosures.</description><subject>Abstracts</subject><issn>2328-8957</issn><issn>2328-8957</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNqFkE1LAzEQhoMoWGrvHnOXrfncTS6CFD8KxQq255Bms2tkmyzJVrS_3l1WRE9eZgZmnpfhAeASozlGkl6HypV9-cA5nWMh6AmYEEpEJiQvTn_N52CW0htCCGPEUSEn4GkTP1vtwzHsNTTxcHRw6StrOhc8dB4-685Z3yW49aWNdXC-hi-hcSVcx1p7uInap7bRvtMDcgHOKt0kO_vuU7C9v9ssHrPV-mG5uF1lBheMZszQAhcEY241FkwawhgRhElWcct3tiolt4hKg3AphNA7RJjNNRe2yBHr6Sm4GXPbw25vS9O_GHWj2uj2On6qoJ36u_HuVdXhXfGcYsZJH4DGABNDStFWPyxGanCqBqdqdKoGpz1yNSLh0P5__QUCUXvT</recordid><startdate>20171004</startdate><enddate>20171004</enddate><creator>Mañez, Noelia</creator><creator>Alderete, Manuel</creator><creator>Benso, Jose</creator><creator>Valledor, Alejandra</creator><creator>Smud, Astrid</creator><creator>Schijman, Alejandro</creator><creator>Besuschio, Susana</creator><creator>Barcan, Laura</creator><general>Oxford University Press</general><scope>TOX</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20171004</creationdate><title>Trypanozoma cruzi Infection in Patients Undergoing Solid Organ Transplantation</title><author>Mañez, Noelia ; Alderete, Manuel ; Benso, Jose ; Valledor, Alejandra ; Smud, Astrid ; Schijman, Alejandro ; Besuschio, Susana ; Barcan, Laura</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1743-4c37172115ea1849c244282494f5e5befd95e039c01d888ab024e6a58e76044c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Abstracts</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mañez, Noelia</creatorcontrib><creatorcontrib>Alderete, Manuel</creatorcontrib><creatorcontrib>Benso, Jose</creatorcontrib><creatorcontrib>Valledor, Alejandra</creatorcontrib><creatorcontrib>Smud, Astrid</creatorcontrib><creatorcontrib>Schijman, Alejandro</creatorcontrib><creatorcontrib>Besuschio, Susana</creatorcontrib><creatorcontrib>Barcan, Laura</creatorcontrib><collection>OUP_牛津大学出版社OA刊</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Open forum infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mañez, Noelia</au><au>Alderete, Manuel</au><au>Benso, Jose</au><au>Valledor, Alejandra</au><au>Smud, Astrid</au><au>Schijman, Alejandro</au><au>Besuschio, Susana</au><au>Barcan, Laura</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Trypanozoma cruzi Infection in Patients Undergoing Solid Organ Transplantation</atitle><jtitle>Open forum infectious diseases</jtitle><date>2017-10-04</date><risdate>2017</risdate><volume>4</volume><issue>suppl_1</issue><spage>S702</spage><epage>S702</epage><pages>S702-S702</pages><issn>2328-8957</issn><eissn>2328-8957</eissn><abstract>Abstract Background It is estimated that 1.5 million people are infected with T. cruzi in Argentina (4%). Chagas reactivation rate (R) in patients with solid organ transplantation (SOT) is around 33%, being higher in cardiac transplantation (Tx). Objective To describe the clinical characteristics, evolution, mortality, to evaluate reactivation risk factors and to analyze the usefulness of molecular tests in patients undergoing at SOT with Chagas’ disease risk (ChR) (R or Donor-derived transmission, -DT-), in a hospital in our country. Methods Retrospective cohort from all the patients who received an SOT in our hospital from January 1988 to March 2017. All patients with ChR: either R or DT were analyzed. Inclusion: survival more 30 days and 6 months of follow-up or until death. We performed post-Tx monitoring with parasitaemia (Strout), and serial whole blood polymerase chain reaction (PCR) testing, weekly until 2 months, every 2 weeks until the sixth month and monthly until the year, later annual. PCR monitoring is done since 2006. Results We performed 1932 SOT in 29 years: 54 SOT in patients with ChR, 46 chagasic recipients (CR) and 8 chagasic donors (CD) to negative recipient 24/46 (52%) presented R, (see Table 1), 4 had more than one episode. Time to first R was 67 days (r = 3–296, median 30 days). At the time of the R Strout was performed in 19 episode 13 were negative, PCR was positive in 10/10 of perfcormed test, 32% vs. 100% (P = 0.001). Clinical R: 5 episode in 4 patients (panniculitis 3, 1 with myocarditis, 1 myocarditis). Strout was negative in 2 of these, in the other episode monitoring had not been performed. Immunosuppression (IS): there were no differences in the IS, (induction and treatment of rejections). Reactivation: 21/24 responded to treatment, 2 spontaneously PCR-negative, 1 died. Mortality: 6/24 (25%) in pt. R and 2/17 (12%) in pt no R (P = ns), not related mortality. DT occurred in 1/ 3 liver and in 0/5 renal recipients. Type of Tx All Reactivation Clinic Liver (L) 786 7/26 (27%) 1/7 (14%) Heart 241 13/23 (56%) 2/13 (15%) Kidney (K) 613 2/5 (40%) 1/2 (50%) Lung 105 1/2 (50%) 0 LK 26 1/1 (100% 0 Others 161 0 0 Conclusion PCR was more sensitive than Strout for detection of R or transmission. There was no clinical R in pt monitored by PCR. Also PCR sensitivity allow safe acceptance of Chagasic organs. Disclosures All authors: No reported disclosures.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/ofid/ofx163.1883</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2328-8957
ispartof Open forum infectious diseases, 2017-10, Vol.4 (suppl_1), p.S702-S702
issn 2328-8957
2328-8957
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5631452
source OUP_牛津大学出版社OA刊; PubMed Central
subjects Abstracts
title Trypanozoma cruzi Infection in Patients Undergoing Solid Organ Transplantation
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T09%3A33%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Trypanozoma%20cruzi%20Infection%20in%20Patients%20Undergoing%20Solid%20Organ%20Transplantation&rft.jtitle=Open%20forum%20infectious%20diseases&rft.au=Ma%C3%B1ez,%20Noelia&rft.date=2017-10-04&rft.volume=4&rft.issue=suppl_1&rft.spage=S702&rft.epage=S702&rft.pages=S702-S702&rft.issn=2328-8957&rft.eissn=2328-8957&rft_id=info:doi/10.1093/ofid/ofx163.1883&rft_dat=%3Coup_pubme%3E10.1093/ofid/ofx163.1883%3C/oup_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1743-4c37172115ea1849c244282494f5e5befd95e039c01d888ab024e6a58e76044c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/ofid/ofx163.1883&rfr_iscdi=true